Samantha Johnson

Coordinating Assistant/ Director of Advertising and Recruitment
A bespectacled, young white woman with long brown hair all the way up to her elbows


  • Owensboro Community and Technical College, Owensboro Kentucky 


  • Coordinating Assistant – Research Integrity, LLC

Training & Qualifications

  • IATA: computer training; current certificate holder
  • IATA: computer training; current certificate holder
  • GCP CITI; current certificate holder
  • All patient related interviews, procedures, and contacts according to various protocols (Since 2022)
  • Consenting Patients (since 2022)
  • Inclusion/Exclusion review (since 2022)
  • Patient Recruitment (Since 2022)
  • Patient Retention (Since 2022)
  • Obtain Medical Records for PI review (since 2022)
  • Watch over Rights and Welfare of the Patients (since 2022)
  • Attends Investigator Meetings (Since 2022)
  • Assist PI in delegated duties (since 2022)
  • Electronic Diaries: sponsor- and vendor- provided training (since 2022)
  • EKG Acquisitions: site training per cardiologist; lead placement per sponsor recommendations (since Feb 2022)
  • EKG Transmission: per sponsor & vendor training; both computer/phone line (since 2022)
  • Vitals: include temp, wt, ht, BP, HR; site training; manual/automatic BP; oral, temporal, auricle temp (since 2022)
  • Electronic source documents: sponsor and vendor training (since 2022)
  • EDC Experience: sponsor training; includes Medidata Rave, InForm, Oracle, Calyx, Integrium, Medrio, Science37, ClinTrak, eCaselink
  • Performs Artirial Velocity (since 2022)
  • IXRS; sponsor training (since Feb 2021)

Clinical Research

  • Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or Atherosclerotic Cardiovascular Disease Who are Not Adequately Controlled by Their Lipid-Modifying Therapies
  • A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor Xia Inhibitor, Versus Apixaban in Participants with AF (LIBREXIA-AF) • TestCard Pregnancy Test Kit
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 for Major Depressive Disorder (The RELIANCE-II Study)
  • TestCard Pregnancy Test Kit
  • A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder (RELIANCE-OLS)
  • A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trail to Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy
  • A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate Between 20 and 60 mL/min/1.73 m2
  • A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with AF (AZALEA)
  • A Phase 1a/b Randomized, Single-Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Healthy Volunteers and Multiple Ascending Doses of AZD3427 in Patients with Heart Failure (HFrEF and HF with EF > 41%)
  • A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
  • A Multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and oler with AF at risk for stroke.
  • A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension 
  • A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination with Ezetimine 10 mg Daily as an Adjunct to High-Intensity Statin Therapy (The ROSE 2 Study)
  • A mulit-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries